Unknown

Dataset Information

0

Past, Present and Future of Bacillus Calmette-Guerin Vaccine Use in China


ABSTRACT: The BCG vaccine is prepared from a weakened strain of Mycobacterium bovis (M. bovis), a bacterium closely related to Mycobacterium tuberculosis (MTB), which causes tuberculosis (TB). The vaccine was developed over 13 years, from 1908 to 1921, in the French Institut Pasteur by Léon Charles Albert Calmette and Jean-Marie Camille Guérin, who named the product Bacillus Calmette–Guérin (BCG). BCG, the only licensed vaccine currently available to prevent TB, is given to infants at high risk of TB shortly after birth to protect infants and young children from pulmonary, meningeal, and disseminated TB. The BCG vaccine, one of the safest and most widely used live attenuated vaccines in the world, recently celebrated its 100th anniversary (from 1921 to 2021); its record of use in preventing TB in China is also approaching 100 years. In 2022, a new century of BCG vaccine immunization will begin. In this article, we briefly review the history of BCG vaccine use in China, describe its current status, and offer a preliminary outlook on the future of the vaccine, to provide BCG researchers with a clearer understanding of its use in China.

SUBMITTER: Li J 

PROVIDER: S-EPMC9320669 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7921379 | biostudies-literature
| S-EPMC7564904 | biostudies-literature
| S-EPMC7835355 | biostudies-literature
| S-EPMC8343811 | biostudies-literature
| S-EPMC9543886 | biostudies-literature
| S-EPMC4113786 | biostudies-literature
| S-EPMC3127204 | biostudies-literature
| S-EPMC7212995 | biostudies-literature
| S-EPMC2929629 | biostudies-literature
| S-EPMC6361786 | biostudies-literature